Predictive Oncology Inc. has announced that it has been granted an extension by the Nasdaq Hearings Panel to remain listed on The Nasdaq Capital Market. Following a hearing on July 17, 2025, the company was notified on July 23, 2025, that it has until December 8, 2025, to comply with continued listing requirements. This extension comes after Predictive Oncology Inc. was initially notified of a potential delisting due to not meeting the required stockholders' equity and minimum bid price standards. The company is actively working on measures to meet these requirements by the end of the extension period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Predictive Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-004685), on July 24, 2025, and is solely responsible for the information contained therein.